Lacosamide Teva

Lacosamide, the active ingredient in Lacosamide Teva, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve disease control.

GNH USA supplies Lacosamide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. With a focus on regulatory compliance, GNH USA ensures product integrity throughout the supply chain, supporting healthcare providers in delivering effective epilepsy care.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. Adjunct therapy in refractory focal epilepsy: provides additional seizure control when other medications are insufficient. Epilepsy management: contributes to overall seizure reduction as part of a comprehensive treatment plan. Monotherapy for focal seizures: may be used alone in newly diagnosed patients. Combination therapy: enhances efficacy when combined with other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Hypersensitivity reactions including anaphylaxis - Elevated liver enzymes or hepatic dysfunction

When prescribing lacosamide, clinicians should consider several safety factors.

Renal impairment: assess renal function and consider dose adjustment. Hepatic impairment: monitor liver enzymes and adjust dosing if needed. Cardiac conduction: monitor PR interval, especially in patients with pre‑existing heart disease. Concomitant antiepileptics: watch for increased CNS depression. Pregnancy: safety not established; discuss risks with healthcare provider. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Drugs that prolong PR interval (e.g., quinidine, class Ia antiarrhythmics): increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, topiramate): may increase side‑effect burden. - Alcohol: may enhance central nervous system depression. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy; consider additional methods.